Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 7(3): 359-365.

Author(s): Yuki Ishii, Samuel Waxman and Doris Germain.

Affiliation: Mount Sinai School of Medicine,Department of Medicine, Division of Hematology/Oncology, One Gustave L. Levy Place, Box 1178, New York, NY 10029, USA.


The ubiquitin-proteasome pathway plays a central role in the degradation of proteins involved in several pathways including the cell cycle, cellular proliferation and apoptosis. Bortezomib is the first proteasome inhibitor to enter clinical use, and received approval by the Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma, therefore validating inhibition of the proteasome as an anticancer target. The approval of Bortezomib was based on a large, international, multicenter phase III trial showing its efficacy and safety compared with conventional therapy. Preclinical data also demonstrates the synergistic effect of bortezomib with other chemotherapeutic agents and its ability to overcome drug resistance. Since then several other proteasome inhibitors have been developed. The anti-tumor activities of bortezomib have been attributed to its effect on pro-apoptotic pathways including the inhibition of NF-κB and induction of endoplasmic reticulum stress. However, the molecular mechanisms are not fully understood. In this review, we will summarize the molecular mechanism of apoptosis by bortezomib.


dependent proteolysis, proteasome, bortezomib-induced apoptosis, cyclin D1.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 7
Issue Number: 3
First Page: 359
Last Page: 365
Page Count: 7
DOI: 10.2174/187152007780618180
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science